Literature DB >> 9531265

Intercellular and intracellular events following the MHC-unrestricted TCR recognition of a tumor-specific peptide epitope on the epithelial antigen MUC1.

J Magarian-Blander1, P Ciborowski, S Hsia, S C Watkins, O J Finn.   

Abstract

We examined the functional and molecular parameters involved in direct TCR recognition of a tumor-specific peptide epitope on the tumor Ag MUC1. This peptide epitope is tandemly repeated and recognized on the native molecule rather than processed and bound to the MHC. Even though the TCR was not MHC restricted, intercellular interactions found to facilitate this recognition included intercellular adhesion molecule-1/LFA-1, LFA-3/CD2, and class I/CD8. Intracellular parameters of MHC-unrestricted CTL activation were examined to compare the recognition of the MUC1 epitope presented on synthetic microspheres, with the recognition of the native epitope in the context of other molecules on the target cells. The epitope on microspheres induced a transient influx of Ca2+ that was not accompanied by detectable tyrosine phosphorylation of the zeta-associated protein ZAP-70, whereas recognition of MUC1 epitopes on tumor cells caused a sustained Ca2+ influx and ZAP-70 phosphorylation. The transient influx of Ca2+ was not sufficient to cause translocation of the nuclear factor of activated T cells (NF-AT) into the nucleus or CTL proliferation. In contrast, recognition of the MUC1 epitope on tumor cells resulted in full activation of the CTL, nuclear translocation of NF-AT, and proliferation. MHC-unrestricted TCR triggering, therefore, involves similar intercellular and intracellular events that participate in the conventional, MHC-restricted Ag recognition. Direct recognition of the MUC1 peptide epitope by the TCR in the absence of presentation by the MHC induces a partial signal that is completed by further interactions of other receptor/ligand pairs on the surface of the CTL and their target cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9531265

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

1.  How structural adaptability exists alongside HLA-A2 bias in the human αβ TCR repertoire.

Authors:  Sydney J Blevins; Brian G Pierce; Nishant K Singh; Timothy P Riley; Yuan Wang; Timothy T Spear; Michael I Nishimura; Zhiping Weng; Brian M Baker
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-16       Impact factor: 11.205

2.  Molecular identification of an MHC-independent ligand recognized by a human {alpha}/{beta} T-cell receptor.

Authors:  Ken-ichi Hanada; Qiong J Wang; Takashi Inozume; James C Yang
Journal:  Blood       Date:  2011-02-07       Impact factor: 22.113

3.  Therapeutic potential of a tumor-specific, MHC-unrestricted T-cell receptor expressed on effector cells of the innate and the adaptive immune system through bone marrow transduction and immune reconstitution.

Authors:  Nehad M Alajez; Jan Schmielau; Mark D Alter; Michael Cascio; Olivera J Finn
Journal:  Blood       Date:  2005-03-03       Impact factor: 22.113

Review 4.  Cancer vaccines: translation from mice to human clinical trials.

Authors:  Hoyoung Maeng; Masaki Terabe; Jay A Berzofsky
Journal:  Curr Opin Immunol       Date:  2018-03-16       Impact factor: 7.486

Review 5.  Cytokine-induced NK-like T cells: from bench to bedside.

Authors:  Yeh Ching Linn; Kam M Hui
Journal:  J Biomed Biotechnol       Date:  2010-03-30

6.  Characterization of a novel nonclassical T cell clone with broad reactivity against human renal cell carcinomas.

Authors:  Qiong J Wang; Ken-Ichi Hanada; James C Yang
Journal:  J Immunol       Date:  2008-09-15       Impact factor: 5.422

Review 7.  Prospects for immunotherapy of malignant disease.

Authors:  E C Morris; G M Bendle; H J Stauss
Journal:  Clin Exp Immunol       Date:  2003-01       Impact factor: 4.330

8.  Characterization of the recognition and functional heterogeneity exhibited by cytokine-induced killer cell subsets against acute myeloid leukaemia target cell.

Authors:  Yeh C Linn; Siew Kee J Lau; Bee H Liu; Lee H Ng; Hao X Yong; Kam M Hui
Journal:  Immunology       Date:  2008-09-05       Impact factor: 7.397

Review 9.  MUC1 and the immunobiology of cancer.

Authors:  Joyce Taylor-Papadimitriou; Joy M Burchell; Timothy Plunkett; Rosalind Graham; Isabel Correa; David Miles; Michael Smith
Journal:  J Mammary Gland Biol Neoplasia       Date:  2002-04       Impact factor: 2.698

Review 10.  MUC1 in carcinoma-host interactions.

Authors:  K Denda-Nagai; T Irimura
Journal:  Glycoconj J       Date:  2000 Jul-Sep       Impact factor: 3.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.